Skip to main content
Clinical Trials/IRCT20090117001556N107
IRCT20090117001556N107
Recruiting
Phase 3

Sulforaphane treatment of autism spectrum disorder: a double blind controlled trial

Tehran University of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
50
Status
Recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • DSM\-5 clinical diagnosis of autistic disorder
  • Children between the ages of 3 and 12 years old
  • Presence of behavioral problems such as aggression, overactivity or repetitive behaviors (indication of treatment with risperidone)

Exclusion Criteria

  • Presence of any active medical problem
  • Other psychiatric diagnosis except for mild to moderate Intellectual disability
  • Receiving any antipsychotic medications during past monthprior to the trial
  • Severe hepatic disease
  • History of allergy to risperidone and intolerance of it
  • History of seizure requiring change of antiepileptic dose during the last month
  • Seizure during the last 6 months

Outcomes

Primary Outcomes

Not specified

Similar Trials